( n of a first clinical candidate and ha...)Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology,Health

Critical Therapeutics has a strong HMGB1 intellectual property position that includes 6 U.S. and 17 foreign patents that have issued and 15 U.S. and 53 foreign patents that are currently pending issuance. Critical Therapeutics' HMGB1 patent estate is exclusively licensed to MedImmune for the treatment and prevention of diseases, such as arthritis and lupus. In addition, Critical Therapeutics licensed its HMGB1 diagnostic rights to Beckman Coulter, Inc., which is developing immunoassays to detect and manage inflammatory diseases.

About HMGB1

HMGB1, a pro-inflammatory protein secreted by different cell types, is part of the body's response to trauma and infection. HMGB1 is expressed at high levels beginning 12 to 72 hours after an injury, which is about the time inflammation-associated tissue damage begins. Because of the timing and duration of expression of HMGB1, it may be an important factor in the sequence of events that result in severe tissue damage following injury or during chronic inflammation.

About Arthritis(1)

Arthritis is a term that describes a group of more than 100 medical conditions that collectively affect nearly 70 million adults and 300,000 children in the United States alone. All of these conditions affect the musculoskeletal system and specifically the joints - where two or more bones meet. Arthritis-related joint problems include pain, stiffness, inflammation and damage to joint cartilage and surrounding structures. Rheumatoid arthritis is one of the most serious and disabling forms of the disease, affecting about 2.1 million Americans.

About Lupus(2)

Lupus is a widespread and chronic autoimmune disease that causes the immune system to attack the body's tissue and organs, including the joints, kidneys, heart, lungs, brain, blood, or skin. Approximately 1.5 million Americans have a form of
'"/>